Last updated: 2026-09-06 13:19:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Praxis Precision Medicines, Inc. (PRAX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $351,12, with a market capitalization of $9,82B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $37,19 to $392,70. This page covers its latest market performance, valuation, price trends and company information.
$9,82B | |
$352,99 | |
$914,26 | |
$11,85 | |
$355,15 | |
138,62K | |
457,32K | |
-- | |
$392,70 | |
$37,19 | |
-- | |
-- |
Praxis Precision Medicines, Inc. (PRAX) last closed at $355,15 as of 2026-09-04 23:31:00, unchanged from the previous close of $355,15.
During the latest regular trading session, PRAX traded between $11,85 and $914,26, with a volume of 138,62K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Praxis Precision Medicines, Inc. (PRAX) moved from $367,85 to $351,12, representing a decline of 4,55% ($16,73).
The stock traded between $333,46 and $377,50 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 268,25 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 88,3%
PRAX is currently trading at $351,12, placing it 88,3% of the way from its 52-week low of $37,19 to its 52-week high of $392,70. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 10998 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Praxis Precision Medicines, Inc. (PRAX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.